# Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

> **NCT04341116** · PHASE2,PHASE3 · COMPLETED · sponsor: **I-Mab Biopharma US Limited** · enrollment: 149 (actual)

## Conditions studied

- Coronavirus Disease 2019 COVID-19

## Interventions

- **DRUG:** TJ003234
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04341116
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-11
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04341116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04341116, "Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04341116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*